Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound

Table 1

Prevalence of histomorphologic heterogeneity in human cancers.

Cancer disease site	Total evaluable tumors	Tumor differentiation status			CAlX immunostaining			HIF-1𝛼 immunostaining
		(% of Total)			(% of Total)			(% of Total)
		Well Diff	Mod. Diff	Poorly Diff	<33%	33–67%	>67%	<33%	33–67%	>67%
Head and neck	198	41% (72% CAIX+)	8% (50% CAIX+)	51% (38% CAIX+)	25%	8%	14%	9%	4%	8%
					Total—47% of all tumors			Total—21% of all tumors
Colorectal	57	12% (57% CAIX+)	79% (64% CAIX+)	9% (60% CAIX+)	28%	5%	30%	7%	2%	12%
					Total—63% of all tumors			Total—21% of all tumors
Lung	102	3% (0% CAIX+)	86% (42% CAIX+)	11% (36% CAIX+)	23%	10%	8%	3%	1%	0%
					Total—41% of all tumors			Total—4% of all tumors